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HIV/AIDS is a major cause of infant and 
childhood mortality in Africa.1 For the 
majority of children in Africa access to 
effective care and treatment is limited 
and most of the HIV-infected children in 
Africa will die from preventable, treatable 
childhood illnesses and opportunistic 
infections.  In order to facilitate access 
to appropriate care for HIV-infected 
children, all health care workers looking 
after infants and young children must 
know how to identify HIV infection early, 
and then put in place a management plan 
for each individual child.
HIV/AIDS is incurable and must be 
managed like any chronic illness of 
childhood.  Comprehensive care must 
include prevention, growth monitoring 
and nutrition support, immunisation, 
prevention of opportunistic infections, 
psychosocial support and timeous 
treatment with antiretrovirals (ARV) 
where appropriate.
The care of an HIV-infected child will be 
discussed under the following headings:
•    Early diagnosis of HIV infection in 
children
•    Clinical manifestations of HIV disease 
in children
•    Staging HIV infection and disease in 
children
•    Medical management of HIV disease in 
children.
Early diagnosis of HIV infection 
in children
Perinatal transmission of HIV infection 
accounts for the majority of childhood 
HIV infections. The diagnosis of HIV 
begins with the identification and 
appropriate management of HIV-positive 
pregnant women.  Awareness of the HIV 
status of pregnant women allows for early 
identification of HIV-exposed babies 
and potential for early diagnosis of HIV-
infected babies.
Early diagnosis in HIV-exposed infants 
remains difficult in most settings because 
of the presence of transplacentally acquired 
IgG antibodies, which may persist for 
up to 18 months.  The diagnosis of HIV 
infection in infants relies exclusively on 
virological assays.
Timing of virological tests
The HIV DNA PCR is the most widely 
used virological test due to considerations 
of accuracy and performance times. 
However, this test is costly and assays 
require technical expertise which may not 
be universally available.
An HIV DNA PCR done at birth on HIV-
exposed infants will identify only 30 - 50% 
of HIV-infected babies. In up to 70% of 
HIV-infected babies evidence of viral 
infection develops days to weeks after 
birth.  In the absence of breastfeeding the 
sensitivity and specificity of the HIV DNA 
PCR approaches 100% by 6 weeks of age.2 
While the gold standard of diagnosing 
HIV infection in infants remains two 
concordant HIV DNA PCRs done at 6 
weeks and 4 months of age, the South 
African Guidelines3 recommend one test 
in all HIV-exposed infants 6 weeks and 
older. The results of the one test must be 
interpreted in the context of the clinical 
picture of the child. If a child is breastfed, 
the HIV DNA PCR test must be repeated 
6 weeks after cessation of breastfeeding. In 
infants and children above 18 months of 
age, HIV ELISA can be used to diagnose 
HIV infection accurately.
Clinical manifestation of HIV 
infection in children 
Table I lists the clinical signs or conditions 
that may suggest HIV infection.
Staging HIV infection and disease 
in children
It is always important to examine and stage 
children with HIV infection.  Clinical 
staging is a standardised method for:
•   determining disease stage and/or 
progression
•   strengthening clinical diagnosis when 
laboratory testing is not available
•  the basis of treatment decisions.
The WHO4 has developed a four-stage 
system for paediatric HIV infection 
(revised in 2006), which is similar to 
the adult system (Table II). The other 
international staging system that is widely 
used is the US Centers for Disease Control 
and Prevention (CDC) clinical staging 
system.
The WHO paediatric staging of HIV/AIDS 
is given in Table II.
Immunological staging
The immunological staging system as 
developed by the CDC is based on CD4 
counts by age and is also used mainly to 
make treatment decisions (Table III).
Medical management of children 
with HIV disease
It is important to note that however limited 
the resources are, there is always something 
that can be done for the individual child 
with HIV disease.  Effective medical care 
of children with HIV disease minimises 
disease manifestations and maximises 
quality of life for each child.  All children 
with suspected or confirmed HIV infection 
must have access to:
•  monitoring of growth and development
•  nutritional care and support
•   prophylaxis and treatment of all oppor-
tunistic infections
•  treatment of all incidental disease
•   routine immunisations (EPI) and 
pneumococcal vaccine where available
•  antiretroviral therapy when appropriate.
Monitoring of growth and 
development
Growth failure or failure to thrive is a 
recognised common finding in children 
with HIV disease.  Growth can also be 
used as a sensitive indicator of disease 
progression.  The aetiology of this growth 
failure is multifactorial and includes the 
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hoea5), inadequate macronutrient (protein/
calories) or micronutrient (vitamins/
minerals) intake or a combination of 
factors.
At initial evaluation, the weight, height/
length and head circumference of all 
children 2 years of age and younger must 
be carefully determined. The NCHS 
percentile charts must be used and updated 
regularly to monitor growth trends and to 
address growth failure.  Developmental 
status must also be assessed and children 
with abnormalities must be referred for 
assessment by the appropriate specialists.
Nutritional care and support
The immunodeficiency of HIV infection 
can be exacerbated by malnutrition with 
associated accelerated disease progression 
and mortality.5 Nutritional care and 
support must form an integral part of 
management of children with HIV disease. 
Nutritional care and support does not have 
to wait until signs of malnutrition develop 
and must include dietary instruction 
based on readily available foods, food 




Pneumocystis carinii pneumonia (PCP) 
caused by Pneumocystis jiroveci (PJ) 
remains an important cause of death 
in children with HIV infection. The 
incidence of PCP peaks at 4 - 5 months 
of age and the risk of PCP in the first 
year of life in HIV-infected children not 
receiving PCP prophylaxis is up to 20%. 
Co-trimoxazole prophylaxis significantly 
reduces both the incidence and severity 
of PCP.  In a randomised clinical trial 
conducted in Zambia6 mortality declined 
by 43% and hospital admissions by 23% in 
the co-trimoxazole group when compared 
with the placebo group.  This benefit of 
co-trimoxazole was demonstrated at all 
ages and all levels of CD4 percentage.  Co-
trimoxazole is administered once daily on 
every day of the week.  The recommended 
approximate dosages are listed in Table 
IV.
In a child who cannot tolerate co-
trimoxazole or where co-trimoxazole 
is contraindicated the alternative is to 
use dapsone 2 mg/kg once daily (up to a 
maximum of 100 mg/day).
Co-trimoxazole prophylaxis is recomm-
ended for:
•    all HIV-exposed infants starting at 4 - 6 
weeks of age and continued until HIV 
infection can be reliably excluded
•    breastfed HIV-exposed children at any 
age until infection can be excluded 6 
weeks after cessation of breastfeeding
•    children above 1 year of age who are 
symptomatic (WHO stages II, III, IV) 
or with CD4% below 25%
•    protection against invasive bacterial 
disease, Streptococcus pneumoniae, 
toxoplasmosis and non-typhoid 
Salmonella. 
Co-trimoxazole prophylaxis must be seen 
as lifesaving and must form the basis of 
standard care in HIV-infected children.
Immunisation of children with 
HIV disease
Children with HIV disease are more vulner-
able to severe, recurrent or unusual infections 
by vaccine-preventable path-ogens. While 
it is recognised that in this group of patients 
responses to immun-isation may be subo-
ptimal, routine immunisation is considered 
to be both safe and beneficial.7 Immunisations 
should generally be offered early before the 
onset of HIV-induced immune attrition.
In areas where tuberculosis is endemic, 
the recommendation is that all newborn 
babies, irrespective of HIV exposure, must 
be routinely immunised with the Bacille 
Calmette-Guérin (BCG) vaccine. The risk 
for developing BCG-related complications 
exits,8 but giving BCG immediately after 
birth minimises this risk. Theoretical 
Table I.  Clinical signs or conditions that may suggest HIV infection
Specificity for HIV infection  Signs/conditions
Signs/conditions very specific to  •  Pneumocystic pneumonia
HIV infection    •  Oesophageal candidiasis
     •  Extrapulmonary cryptococcosis
     •  Invasive Salmonella infection
     •  Lymphoid interstitial pneumonitis
     •  Herpes zoster (shingles) with  
         multi-dermatomal involvement
     •  Kaposi’s sarcoma
     •  Lymphoma
     •   Progressive multifocal encepha-
lopathy
Signs/conditions common in HIV-  •  Severe bacterial infections,         
infected children and uncommon      particularly if recurrent
in uninfected children   •  Persistent or recurrent oral thrush
     •  Bilateral painless parotid enlarge- 
         ment
     •  Generalised persistent non-ingui- 
         nal lymphadenopathy
     •  Hepatosplenomegaly (in non-ma- 
         laria endemic areas)
     •  Persistent and/or recurrent fever
     •  Neurological dysfunction
     •   Herpes zoster (shingles), single 
dermatone
     •   Persistent generalised dermatitis 
unresponsive to treatment
Signs/conditions common in HIV-  •  Chronic, recurrent otitis with ear  
infected children but also       discharge
common in ill uninfected children  •  Persistent or recurrent diarrhoea
     •  Severe pneumonia
     •  Tuberculosis
     •  Bronchiectasis
     •  Failure to thrive
     •  Marasmus
Adapted from:  Tindiyebwa D, et al.1
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concerns that immunisations may 
accelerate the course of HIV infections 
are not supported by available data.9 The 
policy is that all children irrespective 
of HIV exposure or infection must be 
immunised according to the national EPI 
guidelines. Pneumovax should be available, 
as a routine vaccine to all HIV-infected 
children because of the seriousness of 
pneumococal infections. 
Antiretroviral therapy in children 
with HIV disease
ART has only recently been available in 
public hospitals in South Africa, and health 
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Table II.  WHO paediatric staging of HIV/AIDS4
Stage   Symptoms
Stage I   •   Asymptomatic
   •   Persistent generalised lymphadenopathy (PGL)
Stage II   •   Unexplained persistent hepatosplenomegaly
   •   Papular pruritic eruptions
   •   Extensive wart virus infection
   •   Extensive molluscum contagiosum
   •   Fungal nail infections
   •   Recurrent oral ulcerations
   •   Unexplained persistent parotid enlargement
   •   Lineal gingival erythema
   •   Herpes zoster 
   •   Recurrent or chronic upper respiratory infections (otitis media, otorrhoea, sinusitis or tonsillitis)
Stage III   •   Unexplained moderate malnutrition not adequately responding to standard therapy
   •   Unexplained persistent diarrhoea (14 days or more)
   •   Unexplained persistent fever (above 37.50 C intermittent or constant, for longer than 1 month)
   •   Persistent oral candidiasis (after first 6 - 8 weeks of life)
   •   Oral hairy leukoplakia
   •   Acute necrotising ulcerative gingivitis/periodontitis
   •   Lymph node tuberculosis
   •   Pulmonary tuberculosis
   •   Severe recurrent bacterial pneumonia
   •   Symptomatic lymphoid interstitial pneumonitis
   •   Chronic HIV-associated lung disease including bronchiectasis
   •   Unexplained anaemia (< 8.g/dl), neutropenia (< 0.5 x 109/l), and/or chronic thrombocytopenia (< 50  
        x 109/l)
Stage IV   •   Unexplained severe wasting, stunting or severe malnutrition not responding to standard therapy
   •   Pneumocystis pneumonia
   •   Recurrent severe bacterial infections (e.g. empyema, pyomyositis, bone or joint infection or meningi-  
        tis but excluding pneumonia)
   •   Chronic herpes simplex infection (orolabial or cutaneous of more than 1 month’s duration or visceral  
        at any site)
   •   Extrapulmonary tuberculosis
   •   Kaposi’s sarcoma
   •   Oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs)
   •   Central nervous system toxoplasmosis (after 1 month of life)
   •   HIV encephalopathy
   •   Cytomegalovirus infection:  retinitis or cytomegalovirus infection affecting another organ, with onset 
        at age older than 1 month
   •   Extrapulmonary cryptococcosis (including meningitis)
   •   Disseminated endemic mycosis (extrapulmonary histoplasmosis, coccidiomycosis)
   •   Chronic cryptosporidiosis 
   •   Chronic isosporiasis
   •   Disseminated non-tuberculous myobacterial infection
   •   Cerebral or B-cell non-Hodgkin’s lymphoma
   •   Progressive multifocal leukoencephalopathy
   •   Symptomatic HIV-associated nephropathy or HIV-associated cardiomyopathy
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care providers are still gaining experience in 
the provision of this to children. Children 
who qualify for ART must be referred 
timeously for appropriate treatment. ART 
has been shown to improve morbidity and 
age-related mortality from HIV infection 
and must be offered to all HIV infected 
children who are eligible according to 
national guidelines.
Conclusion
HIV and AIDS in children presents a 
major threat to their well-being.  Every 
HIV-infected child has the right to 
comprehensive care and treatment and all 
health care providers need to be vigilant 
in identifying HIV-infected children early 
and to offer each individual child optimal 
care, including antiretroviral therapy 
where indicated.
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Persistent diarrhoea (PD) is defined by the 
World Health Organization as episodes of 
diarrhoea that last for 14 or more days.1 The 
epidemiology and impact on mortality has 
been well described.2 PD poses challenges 
for investigation and management because 
of the close association with malnutrition 
and increased vulnerability to infections. 
This association often makes it difficult to 
define the initiating event. It is therefore 
imperative that the care of infants with 
PD is directed at nutritional support while 
further investigations and management 
follow. This review highlights the basic 
approach to PD of presumed infectious 
origin and describes selected non-
infectious conditions. The purpose of 
the latter is to illustrate the principles of 
investigation that may broadly be guided 
by knowledge of the epidemiology of 
common conditions, dietary evaluation, 
timing of onset, and presence of extra-
intestinal manifestations.
The reader is referred to the World Health 
Organization (WHO) manual (2005) 
for physicians and other senior health 
workers on the treatment of diarrhoea that 
provides guidelines for the basic approach 
to and management of PD.1 These include 
initial resuscitation and correction of fluid 
and electrolyte impairments, initiation 
of a nutritious diet that may necessitate 
temporary reductions in lactose intake, 
micronutrient/mineral supplementation 
and, where appropriate, use of antibiotics 
for intestinal and extra-intestinal 
infections.
The majority of infants and young children 
in developing countries will benefit from 
the above approach without requiring 
invasive gastrointestinal investigations. 
An important addition to these guidelines, 
and a gap that has been addressed in the 
current WHO guidelines for the integrated 
management of childhood illness,3 would 
be that in regions of high HIV prevalence 
testing for HIV infection is warranted 
early in the course of management. 
HIV testing and staging allows timely 
initiation of antiretroviral therapy. The 
high prevalence of symptomatic HIV in 
children hospitalised with diarrhoea in 
South Africa supports this approach.4 
The HIV epidemic has changed the 
epidemiology of PD in childhood. 
Salmonella spp.2 and Cryptosporidium 
parvum2,5 have assumed increasing 
importance, but are difficult to eradicate. 
The HIV-infected child with prolonged or 
recurrent dysentery requires referral for 
evaluation of possible cytomegalovirus 
disease and rarer conditions such as 
Kaposi’s sarcoma. The long-term goal 
should be to initiate antiretroviral therapy 
before the child reaches this advanced 
stage of HIV disease. 
The challenge for health workers in our 
environment is the child who fails to 
respond to the guidelines described above 
and in whom basic investigations fail to 
reveal an aetiology. In these situations 
a detailed re-evaluation is warranted. 
This includes obtaining a history of 
antibiotics and other medications that 
cause gastrointestinal upset. This is 
crucial in an era where maintenance 
therapy is increasingly used for chronic 
conditions in paediatric practice.  The 
impact on nutrition and quality of life 
Table III.  Immunological classification based on total and % CD4 
count
     Age of child
Immunological category     < 12 months     1 - 5 years 6 - 12 years
       CD4/µl (%)     CD4/µl (%) CD4/µl (%)
No evidence of suppression     ≥ 1 500 (≥ 25)     ≥ 1 000 (≥ 25) ≥ 500 (≥ 25)
Evidence of moderate      750 - 1 499      500 - 999 200 - 499
suppression      (15 - 24)     (15 - 24) (15 - 24)
Severe suppression     < 750 (< 15)     < 500 (< 15) < 200 (< 15)
Table IV.  Co-trimoxazole prophylaxis
Age   Approximate weight           Co-trimoxazole daily dose
6 weeks - 2 months 5 kg                 2.5 ml
2 - 12 months  5 - 9.9 kg                     5 ml
12 - 24 months  10 - 14.9 kg                7.5 ml
24 - 60 months  15 - 21.9 kg               10 ml or 1 tablet
> 60 months  > 22 kg                        15 ml or 1½ tablets
Persis tent diarrhoea
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will often determine the extent to which 
modifications of such treatment regimens 
are required. 
While infectious and post-infectious 
causes are responsible for the majority 
of cases of PD globally and locally, an 
awareness of non-infectious causes is 
necessary, especially in communities 
with wide socioeconomic heterogeneity. 
The proportion of PD attributable to 
non-infectious causes assumes greater 
relevance and deserves attention in the 
setting where the usual risk factors for 
infectious diarrhoea and malnutrition 
are not apparent.  Non-infectious causes 
of PD include among others, cow/soy 
milk protein intolerance, coeliac disease 
(gluten-sensitive enteropathy) and 
cystic fibrosis (secondary to pancreatic 
impairment). The latter are more likely in 
children of Caucasian origin. 
Cow’s milk or formula protein intolerance 
presents within the first 6 months of life, 
usually with persistent and/or blood-
tinged stools and anaemia. A temporal 
association should be sought with 
introduction of formula. This entity may be 
under-recognised in environments where 
dietary iron deficiency is common. Infants 
with anaemia and PD should have stools 
assessed for occult blood to screen for this 
condition prior to dietary manipulation or 
biopsy. It is worth noting that the RAST 
test may be negative in these infants.6 
In older children coeliac disease should be 
considered after a careful search for other 
associated systemic manifestations such 
as anaemia and dermatitis herpetiformis.7 
Besides serological tests small-intestinal 
biopsy is warranted for this condition, 
with assessment of response to dietary 
manipulation. Extensive dietary 
restrictions without any investigations 
must be avoided. Other conditions that 
warrant endoscopic biopsies include 
the congenital causes, autoimmune 
enteropathy and inflammatory bowel 
disease. 
In conditions such as coeliac disease, 
cystic fibrosis, inflammatory bowel disease 
and primary immunodeficiency, other 
systemic manifestations provide clues to 
the necessity for referral and diagnostic 
investigations.7 Unlike the syndromic 
management of PD these conditions 
warrant detailed investigations in tertiary 
centres before definitive treatment is 
instituted. 
Imaging studies are rarely indicated in 
the investigation of PD. However, in 
young infants with recurrent unexplained 
episodes despite appropriate basic 
management one should consider rare 
anatomical causes such as intestinal 
malrotation or chronic small-intestinal 
obstruction or pseudo-obstruction. 
Upper gastrointestinal contrast studies 
with small-bowel follow-through are best 
conducted in centres with expertise in 
interpretation of these investigations.
The entity of toddler’s diarrhoea is 
frequently considered in ambulatory care 
of infants. It should be stressed that this 
entity should only be considered in the 
infant who is not having any complications 
from diarrhoea, that is, there is no evidence 
of growth failure or fluid and electrolyte 
imbalance. The stools are not voluminous 
and may contain undigested food particles 
but never any blood. 
In summary, the contribution of infectious 
causes, HIV and socioeconomic risk 
factors to PD makes most cases amenable 
to existing management guidelines. 
The child who fails to respond or has 
symptoms at an age outside of the peak 
prevalence period or without any of the 
usual risk factors should be referred for 
further evaluation. 
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In 1995 South Africa adopted the 
Convention of the Rights of the Child. 
Article 23 of the Convention states: ‘A 
mentally or physically disabled child 
should enjoy a full and decent life, in 
conditions that ensure dignity, promote 
self reliance and facilitate the child’s active 
participation in the community.’  
Based on research done here in South 
Africa, I hope to illustrate not only 
the burden of disease of children 
with disabilities (in especially) rural 
communities, but also how much still 
needs to be done to achieve the objects 
of the Conventions of the Right of the 
(disabled) child. Until recently the main 
issues increasing paediatric mortality 
and morbidity included infections and 
malnutrition. Even though these are 
still prevalent today, issues regarding 
disabilities (especially intellectual 
disability) have begun to emerge and 
demand due consideration.
Prevalence of disability
The prevalence of childhood disability 
varies, according to local definition of 
disability and the various environmental 
factors, from 5% to 17% of the population. 
According to the last census, there are 
about 200 000 disabled children in South 
Africa under the age of 10, and another 
300 000 between 10 and 20 years of age, 
representing between 2% and 3% of the 
population in these age groups (Census 
2001).  More than likely this represents 
an underestimation of the magnitude 
of the burden of disability.  In these age 
groups physical, intellectual and hearing 
disabilities are the most prevalent.  
In an epidemiological study of 6 692 child-
ren aged 2 - 9 years in the Bushbuckridge 
district a minimum prevalence of 35.6 
per 1 000 of the childhood population 
was observed.1 The majority had mild 
intellectual disability (GIQ 56 - 80) and the 
ratio of mild to severe was 4.5:1. Epilepsy 
(15.5%) and cerebral palsy (8.4%) were the 
most commonly associated disabilities.2 
The prevalence in this study was similar to 
that found in another South African study 
in the Western Cape.2
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In a study in KwaZulu-Natal, using a 
similar epidemiological approach, the 
prevalence of disabilities was found to be 60 
per 1 000 children overall, 28 per 1 000 for 
motor disability, 20 per 1 000 for hearing 
disability, 9 per 1 000 for seizure disorders 
and 2 per 1 000 had visual deficits.3 The 
higher prevalence of disability may be due 
to the inclusion of perceptual disabilities.
In the Bushbuckridge study at least 291 
children in this small isolated rural 
community in South Africa had at least 
1 or more of the 5 researched disabilities. 
It is most likely that these data broadly 
represent the prevalence and plight of 
children with disabilities in most rural 
areas in South Africa.
The majority of these children were 
receiving no, inadequate or inappropriate 
intervention.  These children’s disabilities 
would therefore result in unnecessary life-
long handicap.  
The case for early detection and 
intervention
The importance of primary prevention 
of disability is universally accepted, 
even in the absence of an identified 
aetiology.  Secondary prevention implies 
early identification of disability and 
intervention. Both the need for early 
diagnosis of abnormal development and 
the effectiveness of early intervention 
for actual or potential developmental 
disorders are treated with skepticism by 
many professionals.  Some have a relatively 
hopeless or fatalistic attitude toward major 
disabilities (such as significant mental 
retardation).  Relatively uninformed rural 
communities have even less insight into 
strategies that should be available to help 
their children with special needs, and 
therefore they would be less inclined to 
lobby for or even demand services and 
relevant interventions for their disabled 
children.  
Another misguided notion is that children 
with milder developmental delay (such 
as early language defects) will ‘outgrow’ 
their problems. Both of these attitudes 
delay the treatment of young children and 
may diminish the eventual outcome of the 
intervention programmes.  
It is widely accepted that early experience 
influences all areas of development.  There 
may be critical periods for the achievement 
of certain skills (usually before the age of 
4 years) and an inability to achieve these 
may lead to permanent deficits.  Failure 
to provide early stimulation may not 
only lead to a discontinuation of normal 
development, but may cause actual 
atrophy of sensory ability (e.g. amblyopia 
associated with strabismus).  Furthermore, 
failure to remediate one disability may 
multiply its effects in other developmental 
areas, and may produce secondary 
emotional handicaps.  Parents also need 
a great deal of support, encouragement 
and knowledge to manage their children 
with disabilities.  The prognosis for the 
child is often directly linked to the parents’ 
support, commitment and enthusiasm.  
Identification of children with 
developmental disorders  
A comprehensive paper is already 
published on this topic,4 but a simple 
approach is to consider 5 questions when 
a child is evaluated within the health 
system:
1.  Can the child see?
2.  Can the child hear?
3.   Is language development adequate for 
age?
4.  Could the child have motor delay?
5.  Could the child have cognitive delay?
Some of these milestones have already 
been incorporated into the Road-to-
Health charts.  This is a step in the right 
direction.  It behoves all health workers 
who come into contact with children to 
be alert regarding developmental issues. 
Perhaps developmental milestones should 
be included in the  Integrated Management 
of Childhood Illnesses (IMCI) also.  
Unfortunately it is not only the 
identification of these children that is a 
problem, but also the services available for 
support, intervention and rehabilitation. 
It is ethically questionable to screen for 
developmental delay and disabilities if 
there is no recourse to any intervention. 
It is in this area particularly that our 
children are poorly served.  Services for 
children, beyond diagnosis, are obviously 
inadequate.
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single suture
Treatments for COPD do not appear to prolong survival
Treatments for chronic obstructive pulmonary disease (COPD) give symptomatic relief, but it’s hard to show that they actually save 
lives. Even more data are needed from even larger trials before frustrated specialists can tell if treatment is prolonging lives. The latest, 
supposedly definitive, trial recently ran into problems. The trial was large (N = 6 112) and compared 4 treatments (a long-acting beta-
agonist, an inhaled corticosteroid, both of these combined, and neither of these) for 3 years in patients with COPD. Four out of 10 
patients dropped out of the trial, so the findings were borderline and difficult to interpret. Combination therapy saved more lives than 
the placebo, but only just, and the difference was not significant in the strict statistical sense. Neither of the treatments alone reduced 
mortality compared with placebo. 
So where do these results leave patients? Until there is better evidence, combined treatment with an inhaled steroid and a long-acting 
beta-agonist should probably be reserved for people with severe disease. Others should stick with a long-acting beta-agonist alone. 
Combined treatment reduced exacerbations, improved symptoms, and protected lung function in this trial. But patients given an 
inhaled steroid (alone or in combination) had a significantly increased risk of pneumonia. 
N Engl J Med 2007; 356: 775-789. 
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